Prostate cancer is one of the most prevalent cancers among men and poses a significant health concern, with its incidence on the rise. In Thailand, it is the 4th most common cancer among men (1), ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...